SCHEMBL17748868

SCHEMBL17748868

Brc1ccc2c(c1)C(c1ccccc1)CC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.47
ALOX15 P16050 1/20 0.47
DRD1 P21728 8/20 0.43
DRD2 P14416 4/20 0.43
SIGMAR1 Q99720 1/20 0.42
HTR2A P28223 2/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
PDGFRA P16234 1/20 0.41
PRKACA P17612 1/20 0.41
KDR P35968 1/20 0.41
CDK8 P49336 1/20 0.41
CDK9 P50750 1/20 0.41
ROCK1 Q13464 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
CYP11B2 P19099 1/20 0.41
PDE1B Q01064 1/20 0.41
CYP19A1 P11511 1/20 0.40
KDM1A O60341 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1144004 0.80 PDE1B (0.47) DRD2HTR2AHTR2CHTR2BPDE1B
SCHEMBL12291861 0.80 HTR2A (0.40) DRD1DRD2HTR2AHTR2CHTR2B
SCHEMBL19849979 0.80 TDP1 (0.45) IGF1RALOX15SIGMAR1HTR2AHTR2C
SCHEMBL14215062 0.79 IGF1R (0.47) IGF1RALOX15HTR2AHTR2CHTR2B
SCHEMBL503849 0.77 SIGMAR1 (0.62) IGF1RALOX15SIGMAR1HTR2AHTR2C
SCHEMBL29390302 0.77 SIGMAR1 (0.62) IGF1RALOX15SIGMAR1HTR2AHTR2C
SCHEMBL4552373 0.76 MEN1 (0.40) IGF1RALOX15HTR2AHTR2CHTR2B
SCHEMBL30606845 0.76 SIGMAR1 (0.60) IGF1RALOX15SIGMAR1HTR2AHTR2C
Ammonia Solution, Strong SCHEMBL8210515 0.76 SIGMAR1 (0.60) IGF1RALOX15SIGMAR1HTR2AHTR2C
SCHEMBL28025940 0.76 SIGMAR1 (0.60) IGF1RALOX15SIGMAR1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3218374-B1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH INC (US) 2021-12-29 EP disclosed
CN-107108614-B Substituted pyrrolopyridines as bromodomain inhibitors 基因泰克公司 2021-06-01 CN disclosed
US-10150767-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2018-12-11 US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-30 US disclosed
EP-3218374-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN Genentech, Inc. (US) 2017-09-20 EP disclosed
WO-2016077380-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH, INC. (US) 2016-05-19 WO disclosed
WO-2016077380-A1 SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN GENENTECH, INC. (US) 2016-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342067-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF BRD4, BRDT, BRPF3 IGF1R 3278/4885ALOX15 4124/4885DRD1 2952/4885
US-10150767-B2 Therapeutic compounds and uses thereof BRD4, BRDT, BRPF3 IGF1R 3278/4885ALOX15 4124/4885DRD1 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.